An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis
A Phase 4, Open Label Field Study to Evaluate the Clinical Benefit, Safety, and Pharmacokinetics of Anthim (Obiltoxaximab) When Used in the Treatment of Suspected, Probable, or Confirmed Cases of Inhalational Anthrax Due to B. Anthracis
Sponsor: APCER Life Sciences
A PHASE4 clinical study on Anthrax and Infection, Bacterial, this trial is ongoing. The trial is conducted by APCER Life Sciences and has accumulated 11 data snapshots since 2023. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Unknown PHASE4
Status: Not Yet Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Not Yet Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE4
-
Aug 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE4
-
Feb 2022 — Aug 2023 [monthly]
Not Yet Recruiting PHASE4
▶ Show 6 earlier versions
-
Sep 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE4
-
Apr 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE4
-
Mar 2019 — Apr 2020 [monthly]
Not Yet Recruiting PHASE4
-
Jun 2018 — Mar 2019 [monthly]
Not Yet Recruiting PHASE4
-
Apr 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- APCER Life Sciences
- Centers for Disease Control and Prevention
- Elusys Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.